BioNxt Solutions (TSE:BNXT)
:BNXT
Want to see TSE:BNXT full AI Analyst Report?
Top Page
BioNxt Solutions
(BNXT)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.41
▼(-35.78% Downside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by very weak financial performance (revenue collapse to near zero, persistent multi-million-dollar losses, continued cash burn, and negative equity with debt far exceeding assets). Technicals add some stabilization near the 20-day average, but the stock remains below longer-term moving averages with negative MACD, and valuation support is limited because earnings are negative and no dividend yield is provided.
Positive Factors
Platform-focused business model
BioNxt’s platform approach targets reformulating existing APIs into patient-friendly delivery formats, a durable model that can generate licensing and royalty revenue without the high costs of de novo drug discovery. That business design can create repeatable, asset-light revenue streams if successful.
Negative Factors
Revenue collapse and unstable commercial base
An abrupt fall to essentially zero revenue in 2025 signals a structural loss of commercial activity or contracted sales. That undermines long-term cash generation, reduces partner/license bargaining power, and raises the probability the firm must materially re-establish revenue channels to survive.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-focused business model
BioNxt’s platform approach targets reformulating existing APIs into patient-friendly delivery formats, a durable model that can generate licensing and royalty revenue without the high costs of de novo drug discovery. That business design can create repeatable, asset-light revenue streams if successful.
Read all positive factors
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$52.38M
Dividend YieldN/A
Average Volume (3M)80.86K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth-62.34%
EPS Growth9.80%
CountryCA
Employees25
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding121,810,260
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioNxt Solutions Business Overview & Revenue Model
Company Description
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medication...
How the Company Makes Money
null...
BioNxt Solutions Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 26.98K | 372.25K | 297.44K | 286.50K |
| Gross Profit | -10.90K | 26.98K | 372.25K | 195.62K | 199.48K |
| EBITDA | -6.04M | -4.32M | -6.48M | -11.51M | -19.19M |
| Net Income | -7.03M | -5.31M | -7.72M | -12.38M | -20.64M |
Balance Sheet | |||||
| Total Assets | 591.68K | 569.36K | 1.27M | 1.61M | 9.73M |
| Cash, Cash Equivalents and Short-Term Investments | 55.26K | 32.35K | 363.65K | 136.20K | 1.35M |
| Total Debt | 5.95M | 4.28M | 4.89M | 4.37M | 5.46M |
| Total Liabilities | 9.96M | 8.43M | 6.55M | 5.74M | 8.06M |
| Stockholders Equity | -9.37M | -7.86M | -5.28M | -4.13M | 1.67M |
Cash Flow | |||||
| Free Cash Flow | -5.20M | -3.03M | -5.37M | -6.23M | -12.61M |
| Operating Cash Flow | -5.20M | -3.03M | -5.17M | -6.23M | -12.16M |
| Investing Cash Flow | 87.43K | 56.21K | 100.84K | -3.86K | -5.31M |
| Financing Cash Flow | 5.13M | 2.64M | 5.29M | 5.02M | 16.23M |
BioNxt Solutions Technical Analysis
Negative
0.64
Price Trends
0.50
Negative
0.54
Negative
0.68
Negative
Market Momentum
-0.02
Positive
38.85
Neutral
66.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.50, and below the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.85 is Neutral, neither overbought nor oversold. The STOCH value of 66.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.
BioNxt Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$36.11M | -8.58 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$23.35M | 2.74 | -71.80% | ― | -7.53% | 41.77% | |
50 Neutral | C$59.88M | -10.05 | -19.76% | ― | -100.00% | 87.93% | |
46 Neutral | C$17.61M | -7.68 | -68.32% | ― | 1.96% | -24.60% | |
41 Neutral | C$52.38M | -10.76 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:BNXT
BioNxt Solutions
0.42
-0.12
-22.22%
TSE:ATLE
Willow Biosciences Inc
0.19
-0.01
-7.04%
TSE:QNTM
Quantum Biopharma
9.47
-7.63
-44.62%
TSE:LABS
MediPharm Labs
0.08
<0.01
14.29%
TSE:AVCN
Avicanna
0.14
-0.14
-50.00%
TSE:INNO
InnoCan Pharma
5.12
-5.28
-50.77%
BioNxt Solutions Corporate Events
Business Operations and Strategy
BioNxt Boosts Investor Relations Efforts With New Mandates and 5.15 Million Option Grants
Positive
Feb 28, 2026
BioNxt Solutions has entered new investor relations agreements and issued a total of 5,150,000 stock options to insiders, employees, consultants and investor relations service providers under its stock option plan. The move is aimed at strengtheni...
Business Operations and StrategyPrivate Placements and Financing
BioNxt Wipes Out $2.7 Million Debt Through Share Issuance
Positive
Feb 27, 2026
BioNxt Solutions Inc., a bioscience company focused on advanced drug delivery platforms and diagnostic technologies for autoimmune and neurological indications, operates research and development facilities across North America and Europe while pri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.